Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 577-583

  Serra, Andreas L ^a   Savoca, Reto ^b   Huber, Andreas R ^b   Hepp, Urs ^a   Delsignore, Aba ^a   Hersberger, Martin ^a   Wüthrich, Rudolf P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Calcium; Cinacalcet; Hypercalcaemia; Hyperparathyroidism; Kidney transplantation; PTH

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AZATHIOPRINE; CALCIUM; CINACALCET; CREATININE; CYCLOSPORIN A; DEOXYPYRIDINOLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHATE; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RECURRENT DISEASE; UNSPECIFIED SIDE EFFECT;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; CALCIUM; CREATININE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHATES; PROSPECTIVE STUDIES; QUALITY OF LIFE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33846694280     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl560     Document Type: Article

References (27)

1. Lobo PI, Cortez MS, Stevenson W, Pruett TL. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995; 9: 277-281
2. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: 436-442
3. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am J Kidney Dis 1992; 19: 99-120
4. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-274
5. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 2005; 5: 1934-1941
6. White RE, Pickering A, Spathis GS. Mood disorder and chronic hypercalcemia. J Psychosom Res 1996; 41: 343-347
7. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-1319
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
9. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36® Health Survey Manual and Interpretation Guide. New England Medical Center, The Health Institute, Boston, MA: 1993
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370
11. Herrmann C, Buss C, Snaith RP. HADS-D Hospital Anxiety and Depression Scale - Deutsche Version. Ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin. Testdokumentation und Handanweisung. Huber, Bern: 1995
12. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314
13. McCarron DA, Muther RS, Lenfesty B, Bennett WM. Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 1982; 22: 662-670
14. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476
15. Bonarek H, Merville P, Bonarek M et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999; 56: 642-649
16. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90: 135-141
17. Carnevale V, Dionisi S, Nofroni I et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50: 626-631
18. Savoca R, Bock A, Kraenzlin ME, Schmid HR, Huber AR. An automated 'bio-intact' PTH assay: A step towards standardisation and improved correlation with parathyroid function in renal disease. Clin Chim Acta 2004; 343: 167-171
19. Martin KJ, Juppner H, Sherrard DJ et al. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005; 68: 1236-1243
20. Jespersen B, Randlov A, Abrahamsen J, Fogh-Andersen N, Kanstrup IL. Effects of PTH(1-34) on blood pressure, renal function, and hormones in essential hypertension: The altered pattern of reactivity may counteract raised blood pressure. Am J Hypertens 1997; 10: 1356-1367
21. Boiskin I, Epstein S, Ismail F, Thomas SB, Raja R. Serum osteocalcin and bone mineral metabolism following successful renal transplantation. Clin Nephrol 1989; 31: 316-322
22. Withold W, Friedrich W, Degenhardt S. Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants. Clin Chim Acta 1997; 261: 105-115
23. Taylor AK, Lucken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994; 20: 589-607
24. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
25. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
26. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237
27. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800